{
  "schema_version": "pdp_json_v1",
  "peptide": {
    "canonical_name": "Cagrilintide",
    "short_name": "Cagrilintide",
    "aliases": [
      "am833",
      "amylin analog",
      "cagri",
      "long acting amylin"
    ],
    "classification": {
      "category": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "needs_prescription": false,
      "notes": "Classification describes what Cagrilintide is and the general domain where it appears."
    },
    "status": {
      "category": "investigational_human",
      "jurisdiction": "GLOBAL",
      "last_reviewed": "2026-01-19",
      "human_use_note": "Status reflects how Cagrilintide appears in clinical literature and/or real-world contexts. This is descriptive only."
    },
    "structure": {
      "sequence_oneletter": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "amino_acid_seq": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "molecular_formula": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "molecular_weight": null,
      "structure_image_url": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
    },
    "risk": {
      "current_score": 5,
      "severity": "moderate",
      "likelihood": "possible",
      "evidence_grade": "unknown",
      "developmental_risk": true,
      "unknowns_penalty": true,
      "rationale": "Risk scoring reflects evidence quality, adverse-signal plausibility, and uncertainty. Limited data increases uncertainty.",
      "risk_score": 5
    },
    "sections": {
      "overview": [
        {
          "claim_type": "overview",
          "title": "What it is",
          "population_group": "general",
          "confidence": "unknown",
          "evidence_grade": "unknown",
          "text": "Cagrilintide is a bioactive compound discussed in research and/or clinical contexts. This entry summarizes what it is, what it is studied for, and key evidence limitations without providing protocols.",
          "evidence_refs": [
            "E1"
          ]
        }
      ],
      "use_cases": [],
      "mechanism": [],
      "human_effects": [],
      "preclinical_effects": [],
      "hypothesized_effects": [],
      "time_dynamics": [],
      "risks": [],
      "contraindications": [],
      "monitoring": [],
      "observed_exposure_ranges": [
        {
          "route": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "unit": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "min": null,
          "max": null,
          "frequency": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "duration": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "population_group": "general",
          "notes": "Descriptive only. Observed in studies; not instructions.",
          "evidence_refs": []
        }
      ],
      "developmental_risk_block": [
        {
          "claim_type": "risk",
          "population_group": "adolescent",
          "confidence": "unknown",
          "evidence_grade": "unknown",
          "text": "Developmental risk is flagged due to limited adolescent data and uncertain long-term effects. Endocrine, growth, neurodevelopmental, and metabolic setpoints may be sensitive to perturbation. This section is descriptive only; uncertainty is explicitly acknowledged.",
          "evidence_refs": []
        }
      ],
      "interaction_summary": [],
      "current_outlook_bullets": [
        "a bioactive compound discussed in research and/or clinical contexts",
        "this entry summarizes what it is, what it is studied for, and key evidence limitations without providing protocols",
        "general recovery and resilience interest (anecdotal)",
        "common biohacker curiosity due to community reports",
        "interest in mechanisms suggested by early evidence",
        "used in goal-based stacking discussions (anecdotal)",
        "exploration in wellness communities despite evidence limits"
      ]
    },
    "evidence": [
      {
        "id": "E1",
        "title": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "source_type": "pubmed",
        "source_id": "E1",
        "url": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "published_date": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "evidence_grade": "unknown",
        "notes": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
      }
    ],
    "changelog": [
      {
        "date": "2026-01-19",
        "change_type": "initial_entry",
        "summary": "Initial canonical entry for Cagrilintide",
        "detail": "Generated from queue ingestion (Phase 6). Requires human-authored, evidence-bounded content.",
        "evidence_refs": []
      }
    ],
    "meta": {
      "appears_in_blends": [
        "cagri-sema"
      ],
      "priority": "high",
      "notes_seed": "Investigational long-acting amylin analog studied for weight management; avoid protocol claims and do not present as approved."
    },
    "needs_prescription": false,
    "topics": {
      "primary": [
        "topic_fat_loss_metabolism",
        "topic_hormonal_endocrine"
      ]
    },
    "slug": "cagrilintide"
  },
  "canonical_name": "Cagrilintide",
  "interactions": {
    "drug_classes": [
      "antidiabetics-insulin-glp1"
    ],
    "supplement_classes": [
      "glucose-lowering-supplements"
    ],
    "notes": []
  },
  "practical": {
    "bottom_line": "Cagrilintide is discussed for appetite control and weight-loss support, often alongside GLP-1 medications. It can strongly affect appetite and GI tolerance, and misuse risks are real.",
    "benefits": [
      "appetite control and reduced food noise discussions",
      "weight-loss support discussions, often in combo with GLP-1s",
      "sometimes discussed for “portion control” and adherence to calorie targets"
    ],
    "side_effects_common": [
      "nausea",
      "vomiting or stomach upset",
      "constipation or diarrhea",
      "reduced appetite that can overshoot into under-eating"
    ],
    "side_effects_serious": [
      "severe persistent vomiting or dehydration",
      "severe abdominal pain (urgent evaluation)",
      "fainting or collapse from poor intake or dehydration"
    ],
    "who_should_be_cautious": [
      "people with a history of pancreatitis or severe GI disease",
      "people with eating disorder history or extreme appetite suppression risk",
      "people on diabetes medications (hypoglycemia risk context when combined)",
      "pregnant or breastfeeding individuals",
      "adolescents (high-consequence metabolic manipulation plus limited evidence)"
    ],
    "schema_version": "practical_block_v1"
  }
}
